OncoMatch/Clinical Trials/NCT05350891
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
Is NCT05350891 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for recurrent nasopharyngeal carcinoma.
A Prospective, Single-arm, Multicenter Clinical Study of Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent Nasopharyngeal Carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage AJCC RT1, AJCC RT2, AJCC RT3, AJCC RT4 (AJCC)
AJCC rT1-T4 which can be surgically removed
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiotherapy — initial
≥6 months from the end of initial radiotherapy to recurrence
Cannot have received: radioactive seed implantation
Have received radioactive seed implantation in the treatment area
Cannot have received: anti-PD-1 therapy
Previously received PD-1 monoclonal antibody
Cannot have received: anti-CTLA-4 therapy
Previously received CTLA-4 monoclonal antibody (or any other antibody that acts on T cell co-stimulation or checkpoint pathway) treatment
Lab requirements
Blood counts
white blood cells ≥3.0 x 10^9/L, absolute neutrophil count ≥1.5x 10^9/L, hemoglobin ≥80 g/L, platelets ≥100 x 10^9/L
Kidney function
serum creatinine ≤ 1.5 times ULN
Liver function
bilirubin ≤ 1.5 times ULN, AST and ALT ≤ 3 times ULN
Sufficient organ function a)Hematology: white blood cells ≥3.0 x 10^9/L, absolute neutrophil count ≥1.5x 10^9/L, hemoglobin ≥80 g/L, platelets ≥100 x 10^9/L. b) Liver function: bilirubin ≤ 1.5 times ULN, AST and ALT ≤ 3 times ULN c) International normalized ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN. d) Renal function: serum creatinine ≤ 1.5 times ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify